InvestSMART

Alterity Therapeutics Limited (ASX: ATH) - Announcements

- Current share price for ATH : $0.575

ASX company news and announcements for Alterity Therapeutics Limited (ATH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Alterity Therapeutics Limited (ATH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Alterity Therapeutics Limited (ATH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Alterity Therapeutics Limited (ATH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$125 Application for quotation of securities - ATH 17 Feb 2025 9:07AM $0.011 $0.575 risen by 5,127.27%
$125 Proposed issue of securities - ATH 10 Feb 2025 10:25AM $0.012 $0.575 risen by 4,691.67%
$125 Alterity raises A$40m to Advance ATH434 Development in MSA 10 Feb 2025 10:23AM $0.012 $0.575 risen by 4,691.67%
$125 Ceasing to be a substantial holder 7 Feb 2025 8:21AM $0.012 $0.575 risen by 4,691.67%
$125 Trading Halt 6 Feb 2025 8:55AM $0.012 $0.575 risen by 4,691.67%
$125 Becoming a substantial holder 6 Feb 2025 8:20AM $0.012 $0.575 risen by 4,691.67%
$125 Disclosure under Takeovers Panel GN 20 5 Feb 2025 2:14PM $0.012 $0.575 risen by 4,691.67%
$125 Change in substantial holding 5 Feb 2025 8:23AM $0.013 $0.575 risen by 4,323.08%
$125 Notice Under Section 708A 4 Feb 2025 12:00PM $0.014 $0.575 risen by 4,159.26%
$125 Application for quotation of securities - ATH 4 Feb 2025 11:57AM $0.014 $0.575 risen by 4,159.26%
$125 Proposed issue of securities - ATH 3 Feb 2025 9:58AM $0.012 $0.575 risen by 4,691.67%
$125 Alterity Raises Funds for ATH434 BD and Clinical Activities 3 Feb 2025 9:54AM $0.012 $0.575 risen by 4,691.67%
$125 Application for quotation of securities - ATH 30 Jan 2025 5:01PM $0.018 $0.575 risen by 3,094.44%
$125 ATH434-201 Phase 2 Topline Results Presentation 30 Jan 2025 3:34PM $0.018 $0.575 risen by 3,094.44%
$125 Positive ATH434 Phase 2 Results Led By Clinical Efficacy 30 Jan 2025 9:20AM $0.008 $0.575 risen by 7,087.50%
$125 Trading Halt 28 Jan 2025 8:43AM $0.008 $0.575 risen by 7,087.50%
$125 Quarterly Activities/Appendix 4C Cash Flow Report 24 Jan 2025 2:52PM $0.009 $0.575 risen by 6,664.71%
$125 Application for quotation of securities - ATH 22 Jan 2025 4:50PM $0.009 $0.575 risen by 6,664.71%
$125 ATH shareholder newsletter January 2025 17 Jan 2025 2:43PM $0.009 $0.575 risen by 6,664.71%
$125 Change of Director's Interest Notice x 4 6 Jan 2025 4:17PM $0.010 $0.575 risen by 5,650%
$125 Notification regarding unquoted securities - ATH 31 Dec 2024 8:33AM $0.008 $0.575 risen by 7,087.50%
$125 Alterity Announces Completion of Phase 2 Clinical Trial 4 Dec 2024 9:38AM $0.004 $0.575 risen by 14,275%
$125 Results of Meeting 22 Nov 2024 11:33AM $0.004 $0.575 risen by 14,275%
$125 Presentation to Annual General Meeting 22 Nov 2024 8:57AM $0.003 $0.575 risen by 19,066.67%
$125 Chairman's Address 2024 Annual General Meeting 22 Nov 2024 8:51AM $0.003 $0.575 risen by 19,066.67%

126 - 150 of 547 results

Page 6 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.